Mutations in the nuclear bile acid receptor FXR cause progressive familial intrahepatic cholestasis

DOI: 10.1038/ncomms10713
Nature Communications, 2016, 7, 10713.

#	Paper	IF	Citations
203	Recent advances in understanding and managing cholestasis. **2016**, 5,		35
202	A Specially Designed Multi-Gene Panel Facilitates Genetic Diagnosis in Children with Intrahepatic Cholestasis: Simultaneous Test of Known Large Insertions/Deletions. **2016**, 11, e0164058		26
201	Nuclear receptors as pharmacological targets, where are we now?. **2016**, 73, 3777-80		3
200	Farnesoid X receptor as a regulator of fuel consumption and mitochondrial function. **2016**, 39, 1062-74		12
199	Fr□zeitige Diagnostik ist entscheidend f□ die Prognose. **2016**, 28, 34-41		
198	Bile acids and their receptors. **2017**, 56, 2-9		73
197	Generation of a bile salt export pump deficiency model using patient-specific induced pluripotent stem cell-derived hepatocyte-like cells. **2017**, 7, 41806		23
196	Bile acid homeostasis controls CAR signaling pathways in mouse testis through FXRalpha. **2017**, 7, 42182		13
195	Hepatobiliary Transport of Bile Acids. **2017**, 9-25		
194	The logic of transcriptional regulator recruitment architecture at -regulatory modules controlling liver functions. **2017**, 27, 985-996		13
193	EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. **2017**, 67, 145-172		512
192	Bile Acid-Induced Liver Injury in Cholestasis. **2017**, 143-172		3
191	Contemporary Evaluation of the Pediatric Liver Biopsy. **2017**, 46, 233-252		6
190	Targeting nuclear receptors for the treatment of fatty liver disease. **2017**, 179, 142-157		127
189	Co nowego w cholestazie □□zi□. Cholestaza z prawid□owa aktywno□ci□ gamma-glutamylotranspeptydazy. **2017**, 92, 366-372		
188	Model Systems for Studying the Role of Canalicular Efflux Transporters in Drug-Induced Cholestatic Liver Disease. **2017**, 106, 2295-2301		13
187	Defects in myosin VB are associated with a spectrum of previously undiagnosed low □glutamyltransferase cholestasis. **2017**, 65, 1655-1669		83

186	Klinische Genetik der Gallenwegserkrankungen. **2017**, 12, 7-15	
185	New therapeutic concepts in bile acid transport and signaling for management of cholestasis. **2017**, 65, 1393-1404	114
184	Early indications of ANIT-induced cholestatic liver injury: Alteration of hepatocyte polarization and bile acid homeostasis. **2017**, 110, 1-12	22
183	Hepatic Tmem30a Deficiency Causes Intrahepatic Cholestasis by Impairing Expression and Localization of Bile Salt Transporters. **2017**, 187, 2775-2787	16
182	An expanded role for heterozygous mutations of ABCB4, ABCB11, ATP8B1, ABCC2 and TJP2 in intrahepatic cholestasis of pregnancy. **2017**, 7, 11823	63
181	Approach to Hypertriglyceridemia in the Pediatric Population. **2017**, 38, 424-434	21
180	Cholestasis After Pediatric Liver Transplantation-Recurrence of a Progressive Familial Intrahepatic Cholestasis Phenotype as a Rare Differential Diagnosis: A Case Report. **2017**, 49, 1628-1633	3
179	Biliary bile acids in hepatobiliary injury - What is the link?. **2017**, 67, 619-631	87
178	Sequencing of FIC1, BSEP and MDR3 in a large cohort of patients with cholestasis revealed a high number of different genetic variants. **2017**, 67, 1253-1264	68
177	[Liver biopsy in children and adolescents : Preliminary morphological examinations in diffuse liver disease]. **2017**, 38, 272-277	2
176	Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH). **2017**, 60, 9960-9973	112
175	MYO5B mutations cause cholestasis with normal serum gamma-glutamyl transferase activity in children without microvillous inclusion disease. **2017**, 65, 164-173	84
174	Bilirubin Metabolism and Jaundice. **2017**, 103-134	1
173	Nutrient-sensing nuclear receptors PPAR□and FXR control liver energy balance. **2017**, 127, 1193-1201	86
172	Comprehensive bile acid profiling in hereditary intrahepatic cholestasis: Genetic and clinical correlations. **2018**, 38, 1676-1685	11
171	Variants Associated with Infantile Cholestatic Syndromes Detected in Extrahepatic Biliary Atresia by Whole Exome Studies: A 20-Case Series from Thailand. **2018**, 7, 67-73	10
170	Clinical phenotype and molecular analysis of a homozygous ABCB11 mutation responsible for progressive infantile cholestasis. **2018**, 63, 569-577	10
169	A rare missense variant in associates with lower cholesterol levels. **2018**, 1, 14	5

168	Cryptogenic cholestasis in young and adults: ATP8B1, ABCB11, ABCB4, and TJP2 gene variants analysis by high-throughput sequencing. **2018**, 53, 945-958		33
167	Unexplained cholestasis in adults and adolescents: diagnostic benefit of genetic examination. **2018**, 53, 305-311		10
166	Review article: therapeutic bile acids and the risks for hepatotoxicity. **2018**, 47, 1623-1638		25
165	Natural products as modulators of the nuclear receptors and metabolic sensors LXR, FXR and RXR. **2018**, 36, 1657-1698		59
164	Genetic determinants of cholangiopathies: Molecular and systems genetics. **2018**, 1864, 1484-1490		16
163	Next generation sequencing in pediatric hepatology and liver transplantation. **2018**, 24, 282-293		45
162	Nuclear receptor FXR, bile acids and liver damage: Introducing the progressive familial intrahepatic cholestasis with FXR mutations. **2018**, 1864, 1308-1318		43
161	Long-term outcomes of six patients after partial internal biliary diversion for progressive familial intrahepatic cholestasis. **2018**, 53, 468-471		12
160	Hypothalamus-Pituitary-Adrenal Dysfunction in Cholestatic Liver Disease. **2018**, 9, 660		11
159	[Biliary atresia and congenital cholestatic syndromes : Characteristics before, after and during transition]. **2018**, 59, 1146-1156		1
158	Molecular Mechanisms in Pediatric Cholestasis. **2018**, 47, 921-937		6
157	Progressive familial intrahepatic cholestasis: diagnosis, management, and treatment. **2018**, 10, 95-104		15
156	Jaundice revisited: recent advances in the diagnosis and treatment of inherited cholestatic liver diseases. **2018**, 25, 75		51
155	Nuclear receptors and liver disease: Summary of the 2017 basic research symposium. **2018**, 2, 765-777		11
154	Bile Acid Metabolism in Liver Pathobiology. **2018**, 18, 71-87		149
153	Xenobiotic Nuclear Receptor Signaling Determines Molecular Pathogenesis of Progressive Familial Intrahepatic Cholestasis. **2018**, 159, 2435-2446		6
152	Postprandial FGF19-induced phosphorylation by Src is critical for FXR function in bile acid homeostasis. *Nature Communications*, **2018**, 9, 2590	17.4	33
151	Long-term outcomes after cholecystocolostomy for progressive familial intrahepatic cholestasis. **2018**, 48, 1163-1171		2

150	Progressive Familial Intrahepatic Cholestasis. **2018**, 22, 657-669	80
149	Transcriptional profiling of liver in riboflavin-deficient chicken embryos explains impaired lipid utilization, energy depletion, massive hemorrhaging, and delayed feathering. **2018**, 19, 177	13
148	Network pharmacology combined with functional metabolomics discover bile acid metabolism as a promising target for mirabilite against colorectal cancer.. **2018**, 8, 30061-30070	35
147	New Insights in Genetic Cholestasis: From Molecular Mechanisms to Clinical Implications. **2018**, 2018, 2313675	41
146	Transporters in Drug Development: 2018 ITC Recommendations for Transporters of Emerging Clinical Importance. **2018**, 104, 890-899	113
145	Bile Formation and the Enterohepatic Circulation. **2018**, 931-956	8
144	Biliary transporter gene mutations in severe intrahepatic cholestasis of pregnancy: Diagnostic and management implications. **2019**, 34, 425-435	5
143	Farnesoid X receptor alpha (FXR) is a critical actor of the development and pathologies of the male reproductive system. **2019**, 76, 4849-4859	0
142	The challenges of primary biliary cholangitis: What is new and what needs to be done. **2019**, 105, 102328	45
141	Probiotic Lactobacillus rhamnosus GG prevents progesterone metabolite epiallaopregnanolone sulfate-induced hepatic bile acid accumulation and liver injury. **2019**, 520, 67-72	7
140	Novel compound heterozygote mutations of TJP2 in a Chinese child with progressive cholestatic liver disease. **2019**, 20, 18	16
139	Rheumatologie und Hepatologie: Diagnostik und Therapie von autoimmunen Lebererkrankungen. **2019**, 46,	
138	Targeting FXR in Cholestasis. **2019**, 256, 299-324	34
137	The Enterokine Fibroblast Growth Factor 15/19 in Bile Acid Metabolism. **2019**, 256, 73-93	8
136	Genetic Cholestatic Disorders. **2019**, 227-245	
135	Next-Generation Sequencing in Paediatric Hepatology. **2019**, 767-780	0
134	Familial intrahepatic cholestasis: New and wide perspectives. **2019**, 51, 922-933	29
133	Bile Acids as Metabolic Regulators and Nutrient Sensors. **2019**, 39, 175-200	92

132	Blood-Bile Barrier: Morphology, Regulation, and Pathophysiology. **2019**, 19, 69-87	15
131	Targeted metabolomics analysis of maternal-placental-fetal metabolism in pregnant swine reveals links in fetal bile acid homeostasis and sulfation capacity. **2019**, 317, G8-G16	7
130	Modulation of ABC Transporters by Nuclear Receptors: Physiological, Pathological and Pharmacological Aspects. **2019**, 26, 1079-1112	10
129	Fetal androgen exposure is a determinant of adult male metabolic health. **2019**, 9, 20195	8
128	Effect of food on the pharmacokinetics and therapeutic efficacy of 4-phenylbutyrate in progressive familial intrahepatic cholestasis. **2019**, 9, 17075	4
127	Fine-Tuning of Sirtuin 1 Expression Is Essential to Protect the Liver From Cholestatic Liver Disease. **2019**, 69, 699-716	21
126	Developments in bile salt based therapies: A critical overview. **2019**, 161, 1-13	39
125	Constitutive Androstane Receptor Differentially Regulates Bile Acid Homeostasis in Mouse Models of Intrahepatic Cholestasis. **2019**, 3, 147-159	4
124	Panel-Based Next-Generation Sequencing for the Diagnosis of Cholestatic Genetic Liver Diseases: Clinical Utility and Challenges. **2019**, 205, 153-159.e6	26
123	Atypical Hepatic Mesenchymal Hamartoma: Histologic Appearance, Immunophenotype, and Molecular Findings. **2019**, 22, 365-369	1
122	Probiotic Lactobacillus rhamnosus GG Prevents Liver Fibrosis Through Inhibiting Hepatic Bile Acid Synthesis and Enhancing Bile Acid Excretion in Mice. **2020**, 71, 2050-2066	62
121	Molecular findings in children with inherited intrahepatic cholestasis. **2020**, 87, 112-117	6
120	Tanshinone IIA prevents rifampicin-induced liver injury by regulating BSEP/NTCP expression via epigenetic activation of NRF2. **2020**, 40, 141-154	13
119	Cholestatic Liver Diseases: A Primer for Generalists and Subspecialists. **2020**, 95, 2263-2279	7
118	Neonatal liver disease. **2020**, 56, 1760-1768	
117	Targeted Next-Generation Sequencing in Diagnostic Approach to Monogenic Cholestatic Liver Disorders-Single-Center Experience. **2020**, 8, 414	6
116	Genetic variation in the farnesoid X-receptor predicts Crohn's disease severity in female patients. **2020**, 10, 11725	3
115	Fxr-alpha Skips Alternatively in Liver Metabolism. **2020**, 159, 1655-1657	1

114	Fine tuning the gut-liver-axis. **2020**, 94, 3595-3596		
113	Coagulopathy in Malnourished Mice Is Sexually Dimorphic and Regulated by Nutrient-Sensing Nuclear Receptors. **2020**, 4, 1835-1850		2
112	Pediatric Cholestatic Liver Disease: Review of Bile Acid Metabolism and Discussion of Current and Emerging Therapies. **2020**, 7, 149		19
111	Variants in ABCB4 (MDR3) across the spectrum of cholestatic liver diseases in adults. **2020**, 73, 651-663		17
110	NR1H4-related Progressive Familial Intrahepatic Cholestasis 5: Further Evidence for Rapidly Progressive Liver Failure. **2020**, 70, e111-e113		7
109	Bile Acid Metabolism in Health and Disease. **2020**, 269-285		1
108	Proposal of a liver histology-based scoring system for bile salt export pump deficiency. **2020**, 50, 754-762		
107	Hepatic Adenosine Triphosphate-Binding Cassette Transport Proteins and Their Role in Physiology. **2020**, 313-326		1
106	SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis. *Nature Communications*, **2020**, 11, 240	17.4	35
105	Pathophysiologic Basis for Alternative Therapies for Cholestasis. **2020**, 364-377		1
104	Nerve growth factor induced farnesoid X receptor upregulation modulates autophagy flux and protects hepatocytes in cholestatic livers. **2020**, 682, 108281		2
103	Bile Acids as Signaling Molecules. **2020**, 299-312		2
102	Pediatric Cholestasis: Epidemiology, Genetics, Diagnosis, and Current Management. **2020**, 15, 115-119		3
101	Emerging therapies in primary sclerosing cholangitis: pathophysiological basis and clinical opportunities. **2020**, 55, 588-614		22
100	Biallelic Mutations in the LSR Gene Cause a Novel Type of Infantile Intrahepatic Cholestasis. **2020**, 221, 251-254		6
99	Molecular Physiology of Bile Acid Signaling in Health, Disease, and Aging. **2021**, 101, 683-731		31
98	Paediatric cholestatic liver disorders for the adult gastroenterologist: a practical guide.. **2021**, 12, 404-413		0
97	Childhood Liver Disease and Metabolic Disorders. **2021**, 288-322		

96	Novel mutation of the TJP2 gene in a Chinese child with progressive cholestatic liver disease coexistent with hearing impairment. **2021**, 20, 198-200	
95	Assessment of Adenosine Triphosphatase Phospholipid Transporting 8B1 (ATP8B1) Function in Patients With Cholestasis With ATP8B1 Deficiency by Using Peripheral Blood Monocyte-Derived Macrophages. **2021**, 5, 52-62	1
94	The zonula occludens protein family regulates the hepatic barrier system in the murine liver. **2021**, 1867, 165994	6
93	NTCP Deficiency Causes Gallbladder Abnormalities in Mice and Human Beings. **2021**, 11, 831-839	4
92	Structural basis of tropifexor as a potent and selective agonist of farnesoid X receptor. **2021**, 534, 1047-1052	4
91	Farnesoid X receptor (FXR): Structures and ligands. **2021**, 19, 2148-2159	14
90	Bile Acid Physiology and Alterations in the Enterohepatic Circulation. **2021**, 24-31.e2	0
89	Pediatric Cholestatic Liver Disease. **2021**, 769-785.e5	1
88	Burden of illness of progressive familial intrahepatic cholestasis in the US, UK, France, and Germany: study rationale and protocol of the PICTURE study. **2021**, 21, 247-253	1
87	Behandlung progressiv-familiⷭer intrahepatischer Cholestasen (PFIC). **2021**, 356-361	
86	Differential Diagnosis of Biliary Atresia. **2021**, 113-121	
85	Response Rate and Impact on Lipid Profiles of Obeticholic Acid Treatment for Patients with Primary Biliary Cholangitis: A Meta-Analysis. **2021**, 2021, 8829510	1
84	A Link between Intrahepatic Cholestasis and Genetic Variations in Intracellular Trafficking Regulators. **2021**, 10,	2
83	Vertical sleeve gastrectomy confers metabolic improvements by reducing intestinal bile acids and lipid absorption in mice. **2021**, 118,	7
82	Fibroblast Growth Factor 19: Potential modulation of hepatic metabolism for the treatment of non-alcoholic fatty liver disease. **2021**, 41, 894-904	8
81	Diosgenin alleviates hypercholesterolemia via SRB1/CES-1/CYP7A1/FXR pathway in high-fat diet-fed rats. **2021**, 412, 115388	5
80	Familial Hepatocellular Cholestasis. **2021**, 204-221	
79	A novel compound heterozygous mutation in ABCB4 gene in a pedigree with progressive familial intrahepatic cholestasis 3: a case report. **2021**, 9, 426	0

78	Performance of preclinical models in predicting drug-induced liver injury in humans: a systematic review. **2021**, 11, 6403	10
77	Mechanisms of Bile Formation and the Pathogenesis of Cholestasis. **2021**, 26-35	
76	A New Variant of an Old Itch: Novel Missense Variant in Presenting with Intractable Pruritus.. **2022**, 12, 701-704	
75	Activation of FXR modulates SOCS3/Jak2/STAT3 signaling axis in a NASH-dependent hepatocellular carcinoma animal model. **2021**, 186, 114497	3
74	A Diagnostic Quagmire: PFIC5 Presenting as a Rare Cause of Neonatal Cholestasis. **2021**, 8, e00558	1
73	Progressive familial intrahepatic cholestasis - farnesoid X receptor deficiency due to mutation: A case report. **2021**, 9, 3631-3636	1
72	Progressive Familial Intrahepatic Cholestasis: A´Study in Children From a Liver Transplant Center in´India.. **2022**, 12, 454-460	
71	Dialogs in the assessment of neonatal cholestatic liver disease. **2021**, 112, 102-115	0
70	Autophagy in liver diseases: A review. **2021**, 82, 100973	15
69	Genetic Disorders of Bile Acid Transport. **2021**, 18, 237-242	0
68	FXR in liver physiology: Multiple faces to regulate liver metabolism. **2021**, 1867, 166133	15
67	Deleterious Variants in ABCC12 are Detected in Idiopathic Chronic Cholestasis and Cause Intrahepatic Bile Duct Loss in Model Organisms. **2021**, 161, 287-300.e16	4
66	Intrahepatic Cholestasis, Refractory Epilepsy, Skeletal Dysplasia, Endocrine Failure, and Dysmorphic Features in a Child With a Monoallelic 2q24-32.2 Deletion Encompassing ABCB11. **2021**, 10935266211036084	0
65	NF-Β Regulation of LRH-1 and ABCG5/8 Potentiates Phytosterol Role in the Pathogenesis of Parenteral Nutrition-Associated Cholestasis. **2021**, 74, 3284-3300	1
64	Increased serum delta neutrophil index levels are associated with intrahepatic cholestasis of pregnancy. **2021**, 47, 4189-4195	0
63	Intrahepatic cholestasis of pregnancy in conjunction with a frameshift deletion in FGFR4. **2021**, 46, 101800	1
62	Redox-Dependent Effects in the Physiopathological Role of Bile Acids. **2021**, 2021, 4847941	1
61	The spectrum of Progressive Familial Intrahepatic Cholestasis diseases: Update on pathophysiology and emerging treatments. **2021**, 64, 104317	4

60	Cholestasis in the Premature Infant. **2020**, 47, 341-354	4
59	BRD4 inhibition and FXR activation, individually beneficial in cholestasis, are antagonistic in combination. **2020**, 6,	5
58	Genetic disorders of nuclear receptors. **2017**, 127, 1181-1192	14
57	The Role of Nuclear Receptor Subfamily 1 Group H Member 4 (NR1H4) in Colon Cancer Cell Survival through the Regulation of c-Myc Stability. **2020**, 43, 459-468	5
56	FAMILIAL INTRAHEPATIC CHOLESTASIS IN CHILDREN: PROBLEMS AND PROSPECTS. **2019**, 22, 388-394	2
55	Gene Therapy for Progressive Familial Intrahepatic Cholestasis: Current Progress and Future Prospects. **2020**, 22,	6
54	Molecular overview of progressive familial intrahepatic cholestasis. **2020**, 26, 7470-7484	12
53	Protective effects of catalpol on mitochondria of hepatocytes in cholestatic liver injury. **2020**, 22, 2424-2432	2
52	Expanding etiology of progressive familial intrahepatic cholestasis. **2019**, 11, 450-463	32
51	Liver Transplantation in Progressive Familial Intrahepatic Cholestasis With Normal Gamma-Glutamyl Transferase: Evaluation of Post-Transplant Steatosis and Steatohepatitis. **2021**, In Press,	
50	Novel therapeutic targets for cholestatic and fatty liver disease. **2022**, 71, 194-209	7
49	Cholestases h□patocytaires g□□iques. **2018**, 111-118	
48	Constitutive Androstane Receptor contributes towards increased drug clearance in cholestasis.	
47	Mice Lacking FXR Are Susceptible to Liver Ischemia-Reperfusion Injury.	
46	Hereditäre Lebererkrankungen. **2020**, 63-116	
45	The Role of a NICU Hepatology Consult Service in Assessing Liver Dysfunction in the Premature Infant. **2021**, 2, e031	
44	Clinical Genetics of Cholangiopathies. 1-8	
43	[Clinical and genetic analysis of an infant with progressive familial intrahepatic cholestasis type II]. **2018**, 20, 758-764	

42	Familial Intrahepatic Cholestasis. **2022**, 807-818	
41	Advances in genetic, epigenetic and environmental aspects of rare liver diseases.. **2021**, 65, 104411	
40	Grape Seed Proanthocyanidin Alleviates Intestinal Inflammation Through Gut Microbiota-Bile Acid Crosstalk in Mice.. **2021**, 8, 786682	2
39	Structural insight into the molecular mechanism of cilofexor binding to the farnesoid X receptor.. **2022**, 595, 1-6	2
38	A study of exons 14, 15, and 24 of the ABCB11 gene in Egyptian children with normal GGT cholestasis.. **2022**, 23, 15-15	
37	Transcriptional Control of by the Nuclear Receptor FXR.. **2022**, 23,	1
36	Inherited Disorders of Bilirubin Metabolism. **2022**, 1129-1148	
35	.. **2022**,	0
34	Role of bile acids and their receptors in gastrointestinal and hepatic pathophysiology.. **2022**,	5
33	Cholestatic Liver Diseases of Genetic Etiology: Advances and Controversies.. **2022**,	3
32	Extrahepatic manifestations of progressive familial intrahepatic cholestasis syndromes: presentation of a case series and literature review.. **2022**,	0
31	DRUG TRANSPORT IN THE LIVER. **2022**, 257-282	
30	Discovery of farnesoid X receptor and its role in bile acid metabolism.. **2022**, 548, 111618	1
29	Newer variants of progressive familial intrahepatic cholestasis.. **2021**, 13, 2024-2038	0
28	FOXA2 prevents hyperbilirubinaemia in acute liver failure by maintaining apical MRP2 expression.. **2022**,	0
27	Identification of two novel pathogenic variants of the NR1H4 gene in intrahepatic cholestasis of pregnancy patients.. **2022**, 15, 90	0
26	Iberogast -Induced Acute Liver Injury: A Case Report. **2022**, 1, 601-603	0
25	Gene Therapy for Acquired and Genetic Cholestasis. **2022**, 10, 1238	1

24	The Role of Bile Acids in the Human Body and in the Development of Diseases. **2022**, 27, 3401	1
23	Liver transplantation in an infant with cerebrotendinous xanthomatosis, cholestasis, and rapid evolution of liver failure.	
22	Gut microbiota mediates methamphetamine-induced hepatic inflammation via the impairment of bile acid homeostasis. **2022**, 166, 113208	0
21	Genetics in Familial Intrahepatic Cholestasis: Clinical Patterns and Development of Liver and Biliary Cancers: A Review of the Literature. **2022**, 14, 3421	2
20	Progressive Familial Intrahepatic Cholestasis. **2022**, 2, 1-20	
19	Overview of Progressive Familial Intrahepatic Cholestasis. **2022**, 26, 371-390	0
18	The liver in sepsis: molecular mechanism of liver failure and their potential for clinical translation. **2022**, 28,	0
17	Progressive Familial Intrahepatic Cholestasis. **2022**, 95-126	0
16	Hepatic Deletion of X-box Binding Protein 1 in Farnesoid X Receptor Null Mice Leads to Enhanced Liver Injury. **2022**, 100289	0
15	Bile Acids - A Peek Into Their History and Signaling.	1
14	Eggerthella lenta DSM 2243 Alleviates Bile Acid Stress Response in Clostridium ramosum and Anaerostipes caccae by Transformation of Bile Acids. **2022**, 10, 2025	0
13	Odevixibat: a promising new treatment for progressive familial intrahepatic cholestasis. 1-9	0
12	The Farnesoid X Receptor as a Master Regulator of Hepatotoxicity. **2022**, 23, 13967	1
11	Paeoniflorin alleviates 17□ethinylestradiol-induced cholestasis via the farnesoid X receptor-mediated bile acid homeostasis signaling pathway in rats. 13,	0
10	Regulation of Chromatin Accessibility by the Farnesoid X Receptor Is Essential for Circadian and Bile Acid Homeostasis In Vivo. **2022**, 14, 6191	1
9	Bile acids and their receptors in regulation of gut health and diseases. **2022**, 101210	2
8	The Role of FXR-Signaling Variability in the Development and Course of Non-Alcoholic Fatty Liver Disease in Children. **2022**, 65, 105-111	0
7	Drug-induced liver injury: An overview and update. **2023**,	0

6	Stimulation of the farnesoid X receptor promotes M2 macrophage polarization. 14,	0
5	Potential therapeutic action of tauroursodeoxycholic acid against cholestatic liver injury via hepatic Fxr/Nrf2 and CHOP-DR5-caspase-8 pathway. **2023**, 137, 561-577	0
4	Children with Chronic Liver Disease. **2023**, 69-87	0
3	Bile Acids and Biliary Fibrosis. **2023**, 12, 792	0
2	Combining Panel-Based Next-Generation Sequencing and Exome Sequencing for Genetic Liver Diseases. **2023**, 113408	0
1	Developmental and Inherited Liver Disease. **2024**, 122-294	0